Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Public ClinicalTrials.gov record NCT03738423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to- Severe Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study is to assess the efficacy of REGN3500 monotherapy in Atopic dermatitis (AD), as well as understand the dose-response relationship, compared with placebo treatment, in adult patients with moderate-to-severe AD. Secondary objectives are to: * Assess the safety and tolerability of subcutaneous (SC) doses of REGN3500 monotherapy in adult patients with moderate-to-severe AD * Assess the Pharmacokinetics (PK) of REGN3500 in adult patients with moderate-to-severe AD * Assess the immunogenicity of REGN3500 in adult patients with moderate-to-severe AD
Study identification
- NCT ID
- NCT03738423
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 129 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 13, 2018 (Actual)
- Primary completion
- Mar 13, 2020 (Actual)
- Completion
- Jul 24, 2020 (Actual)
- Last update posted
- Jun 10, 2022
2018 – 2020
United States locations
- U.S. sites
- 31
- U.S. states
- 21
- U.S. cities
- 27
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Birmingham | Alabama | 35209 | — |
| Regeneron Study Site | Phoenix | Arizona | 85006 | — |
| Regeneron Study Site | Scottsdale | Arizona | 85259 | — |
| Regeneron Study Site | Tucson | Arizona | 85718 | — |
| Regeneron Study Site | Little Rock | Arkansas | 72205 | — |
| Regeneron Study Site | Fountain Valley | California | 92708 | — |
| Regeneron Study Site | Fremont | California | 94538 | — |
| Regeneron Study Site | Oceanside | California | 92056 | — |
| Regeneron Study Site | Sacramento | California | 95815 | — |
| Regeneron Study Site | Santa Monica | California | 90404 | — |
| Regeneron Study Site | Jacksonville | Florida | 32256 | — |
| Regeneron Study Site | Macon | Georgia | 31217 | — |
| Regeneron Study Site | Skokie | Illinois | 60077 | — |
| Regeneron Study Site | Evansville | Indiana | 47714 | — |
| Regeneron Study Site | Overland Park | Kansas | 66215 | — |
| Regeneron Study Site | Louisville | Kentucky | 40202 | — |
| Regeneron Study Site | Louisville | Kentucky | 40217 | — |
| Regeneron Study Site | Louisville | Kentucky | 40241 | — |
| Regeneron Study Site | Saint Joseph | Michigan | 49085 | — |
| Regeneron Study Site | Minneapolis | Minnesota | 55402 | — |
| Regeneron Study Site | Las Vegas | Nevada | 89148 | — |
| Regeneron Study Site | Lebanon | New Hampshire | 03756 | — |
| Regeneron Study Site | New York | New York | 10022 | — |
| Regeneron Study Site | Wilmington | North Carolina | 28405 | — |
| Regeneron Study Site | Cincinnati | Ohio | 45231 | — |
| Regeneron Study Site | Norman | Oklahoma | 73071 | — |
| Regeneron Study Site | North Charleston | South Carolina | 29420 | — |
| Regeneron Study Site | San Antonio | Texas | 78218 | — |
| Regeneron Study Site | San Antonio | Texas | 78229 | — |
| Regeneron Study Site | San Antonio | Texas | 78258 | — |
| Regeneron Study Site | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03738423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 10, 2022 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03738423 live on ClinicalTrials.gov.